IRO® Platform Recognized as an Automated, Scalable Solution to Expand Access to Life-Saving Cell and Gene Therapies
London, UK, November 19, 2024 – Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, today announced it has been awarded the 2024 “CGT Innovation Award” by the BioTech Breakthrough Awards program. The award recognizes Ori’s IRO® platform, which is designed to provide superior biological performance, accelerate therapy development and scale the clinical and commercial impact of these life-saving cell therapies.
The BioTech Breakthrough Awards, organized by Tech Breakthrough, is an independent market intelligence organization celebrating the top companies, products, and services driving innovation across the life sciences and biotechnology fields. This year’s award in the CGT Innovation category acknowledges Ori’s pioneering work in advancing next-generation manufacturing solutions for the cell and gene therapy sector.
“We’re honored to receive the Biotech Breakthrough CGT Innovation Award,” said Jason C. Foster, CEO of Ori Biotech. “This recognition underscores Ori’s commitment to collaborating with industry leaders to advance cell and gene manufacturing innovation. The IRO platform is specifically built to overcome today’s CGT manufacturing challenges, providing a flexible solution that reduces costs, increases throughput, and delivers consistent quality, moving the industry toward widespread patient access to life-saving CGT therapies.”
Ori’s approach to CGT manufacturing addresses critical manufacturing barriers that limit patient access, such as high production costs, quality control challenges, and logistical bottlenecks. IRO’s automated, closed modular design and cloud-based data management system allow therapy developers to seamlessly transition from process development to commercial-scale production, providing a flexible solution to accelerate product development. This will ultimately help enable widespread patient access to cell and gene therapies.
“The 2024 BioTech Breakthrough Awards program attracted over 1,500 nominations from 12 countries, showcasing the global drive for biotechnology innovation,” said Bryan Vaughn, Managing Director of BioTech Breakthrough Awards. “Ori Biotech’s IRO platform exemplifies the groundbreaking technology we aim to honor. Ori is redefining CGT manufacturing with an innovative solution that promises to democratize access to advanced therapies.”
To learn more about Ori Biotech and IRO, visit oribiotech.com.
About Ori Biotech
Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori’s next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products’ clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics.
For news and updates, visit oribiotech.com/news-insights